Rapid “epiretinal membrane” development following intravitreal bevacizumab for Coats' disease

Andrew W. Kam, Michelle Hui, Svetlana Cherepanoff, Adrian T. Fung*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)
20 Downloads (Pure)

Abstract

Purpose: To report a case of rapid “epiretinal membrane” (“ERM”) development following intravitreal bevacizumab for juvenile Coats' disease. Observations: A 7-year old boy was followed for four years with asymptomatic stage 2 Coats' disease in his left eye. At age 11, he developed symptomatic cystoid macular edema. Argon laser photocoagulation to the leaking aneurysms failed to improve his vision, which had symptomatically declined to 20/30. Four-months after laser, a single injection of intravitreal bevacizumab was given. Rapid development of an “ERM” was noticed on his first post-injection follow-up at 4 weeks. By 8-weeks post-injection the visual acuity had deteriorated to 20/400. 25 + gauge pars plana vitrectomy with “ERM” peeling was performed, with recovery of vision to 20/30 at the 4 months post-operative visit. Conclusions and importance: Intravitreal bevacizumab may induce rapidly progressive “ERM” in patients with juvenile Coats' disease.

Original languageEnglish
Pages (from-to)75-77
Number of pages3
JournalAmerican Journal of Ophthalmology Case Reports
Volume11
DOIs
Publication statusPublished - 1 Sep 2018

Bibliographical note

Copyright the Author(s) 2018. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Keywords

  • Coats disease
  • Epiretinal membrane
  • Intravitreal bevacizumab

Fingerprint Dive into the research topics of 'Rapid “epiretinal membrane” development following intravitreal bevacizumab for Coats' disease'. Together they form a unique fingerprint.

Cite this